Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia – implications for immunotherapy

Overview
This study demonstrates the generation of T-cell lines targeting WT1, Survivin, MAGE-A3, and PRAME from pediatric ALL patients using autologous DCs and PHA-blasts. The cells showed specific anti-leukemic activity. G-Rex® are referenced as a strategy for scaling up to clinical cell numbers.
What this paper found
Tumor-associated antigen-specific T-cell lines could be generated from all 50 children with acute lymphoblastic leukemia sampled during maintenance chemotherapy, regardless of NCI risk group or lymphocyte count. Peripheral blood mononuclear cells were stimulated with autologous dendritic cells pulsed with peptide libraries of WT1, Survivin, MAGE-A3 and PRAME, then restimulated with peptide-pulsed PHA-blasts. Expansion after three stimulations ranged from 1.2- to 31.4-fold (mean 6.4-fold). Responses against at least one antigen were found in 92% of standard-risk and 96% of high-risk patients. The lines were predominantly CD3-positive effector-memory cells (mean CD3 97.2%). In co-culture with autologous diagnostic blasts from eight patients, 13.6% of blasts remained after three days versus 46.8% with control T cells (p=0.04).
Note: In vitro study; the authors note that it remains to be determined whether the T cells have therapeutic efficacy in patients with ALL.
We show here that TAA-specific T cells can be generated from patients with ALL during maintenance therapy regardless of NCI risk group and in spite of low lymphocyte counts at the time of sample acquisition. — Gerrit Weber, Ignazio Caruana, Rayne H. Rouce, A. John Barrett, Ulrike Gerdemann, Ann M. Leen, Karen R. Rabin, Catherine M. Bollard, Clinical Cancer Research
Study details
- Authors
- Gerrit Weber, Ignazio Caruana, Rayne H. Rouce, A. John Barrett, Ulrike Gerdemann, Ann M. Leen, Karen R. Rabin, Catherine M. Bollard
- Institution
- Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA · Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA · Department of Medicine, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA · Department of Immunology, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA · Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX · Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
- Journal
- Clinical Cancer Research
- Year
- 2013
- Cell type(s)
- CTL Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
Full citation
Weber G, Caruana I, Rouce RH, et al. Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy. Clin Cancer Res. 2013;19(18):5079-5091.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.